Evidence map›Paper›PMID 40934041›Full record

ReviewCancer innovation2025

Extrachromosomal Circular DNA as a Cancer Biomarker: From Diagnosis to Treatment.

Hexin Li, Jiahui Cai, Gang Zhao, Lihui Zou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer innovation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hexin LiClinical Biobank, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine Chinese Academy of Medical Sciences Beijing China.
Jiahui CaiClinical Biobank, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine Chinese Academy of Medical Sciences Beijing China.
Gang ZhaoDepartment of General Surgery Beijing Hospital Beijing China.
Lihui ZouThe Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing Hospital/National Center of Gerontology of National Health Commission Beijing China.ORCID https://orcid.org/0000-0002-6681-407X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extrachromosomal circular DNA (eccDNA) is an emerging class of genetic material that exists outside of the chromosomal genome. These circular DNA molecules are gaining increasing attention as important biomarkers in various cancers because of their roles in gene amplification, genetic heterogeneity, and drug resistance. In this review, we explore in depth the impacts of eccDNAs on cancer biology, their potential to predict treatment sensitivity and resistance, and their involvement in the development of new anticancer therapies. eccDNAs can be used as biomarkers for various tumor types to help diagnose and predict prognosis.

Indexed as

biomarkercancerdiagnosisextrachromosomal circular DNAtreatment

Identifiers

PMID40934041
PMCPMC12417323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.